Last reviewed · How we verify

NCT06114160: Coqueluche-Vac

Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy

Status unknown Last updated 7 November 2023
What this trial tests

trial testing Data collection in Pertussis in 500 participants. Status unknown.

Timeline
1 December 2023
Primary endpoint
1 February 2024
1 May 2024

Quick facts

Lead sponsorUniversité de Reims Champagne-Ardenne
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment500
Start date1 December 2023
Primary completion1 February 2024
Estimated completion1 May 2024

Drugs / interventions tested

Conditions studied

Sponsor

Université de Reims Champagne-Ardenne

Who can join

18 and older, female only, with Pertussis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In France, it has been recommended since 2022 that pregnant women be vaccinated against pertussis from 20 to 36 weeks' gestation. This vaccination schedule is inspired by the Anglo-Saxon model and studies showing the effectiveness of this practice. The aim of this vaccine is to protect the newborn by transferring antibodies from the fetus to the placenta, because Pertussis is a particularly serious disease in newborns.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

Other recruiting trials for Pertussis

Currently open trials in the same condition.

Other Université de Reims Champagne-Ardenne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06114160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing